GAMBARAN PEMBERIAN HEPATOPROTEKTOR
TERHADAP PERUBAHAN KADAR SGOT/SGPT
PADA PASIEN HEPATITIS IMBAS OAT
DI RSUD KAB. KARANGANYAR
Total View This Week0
Total View This Week0
Institusion
Sekolah Tinggi Ilmu Kesehatan Nasional
Author
Tri, Suryani
Subject
RN Pharmacy and Pharmaceutical Mathematics
Datestamp
2021-03-02 03:56:13
Abstract :
Tuberculosis is an infectious disease caused by the bacteria Mycobacterium tuberculosis. Although Anti-Hepatitis drugs have a bactericidal and bacteriostatic ability against Mycobacterium tuberculosis, Anti-Hepatitis drugs also causes side effects, one of which is hepatitis because it uses Anti-Hepatitis drugs. This study discusses hepatitis B in tuberculosis patients in RSUD Kab. Karanganyar in 2019. This research is a descriptive study with retrospective purposes. The study subjects received 69 tuberculosis patients who received inpatient or outpatient Anti-Hepatitis drugs. This study was conducted by observing patient characteristics including sex, age, elevated levels of SGPT and severity of hepatitis due to using Anti-Hepatitis drugs. The results showed that as many as 36 male patients (52.2%) and 33 female patients (47.8%) suffered from tuberculosis with the most age range, namely 46-55 years (34.8%). There were 34 patients (49.3%) who suffered from hepatitis due to using Anti-Hepatitis drugs and were divided into 3 categories, namely the normal category of 27 patients (79.4%), stage 1 of 5 people (14.7%) and stage 2 of 2 patients (5.9%). The conclusion of this research is Temulawak (Curcuma xanthorriza Roxb) can be used as a hepatoprotector so that it can reduce levels of SGOT and SGPT in patients. Based on the stage of severity of respondents who experienced OAT-induced hepatitis from 34 patients (49.3%), it was categorized into three categories: 27 patients (79.4%) in normal category, 5 in Stadium 1 (14.7%), 2 in Stadium 2 (5.9%) ).
Tuberculosis is an infectious disease caused by the bacteria Mycobacterium tuberculosis. Although Anti-Hepatitis drugs have a bactericidal and bacteriostatic ability against Mycobacterium tuberculosis, Anti-Hepatitis drugs also causes side effects, one of which is hepatitis because it uses Anti-Hepatitis drugs. This study discusses hepatitis B in tuberculosis patients in RSUD Kab. Karanganyar in 2019. This research is a descriptive study with retrospective purposes. The study subjects received 69 tuberculosis patients who received inpatient or outpatient Anti-Hepatitis drugs. This study was conducted by observing patient characteristics including sex, age, elevated levels of SGPT and severity of hepatitis due to using Anti-Hepatitis drugs. The results showed that as many as 36 male patients (52.2%) and 33 female patients (47.8%) suffered from tuberculosis with the most age range, namely 46-55 years (34.8%). There were 34 patients (49.3%) who suffered from hepatitis due to using Anti-Hepatitis drugs and were divided into 3 categories, namely the normal category of 27 patients (79.4%), stage 1 of 5 people (14.7%) and stage 2 of 2 patients (5.9%). The conclusion of this research is Temulawak (Curcuma xanthorriza Roxb) can be used as a hepatoprotector so that it can reduce levels of SGOT and SGPT in patients. Based on the stage of severity of respondents who experienced OAT-induced hepatitis from 34 patients (49.3%), it was categorized into three categories: 27 patients (79.4%) in normal category, 5 in Stadium 1 (14.7%), 2 in Stadium 2 (5.9%) ).
Download
book
BibTex
Latex, Jabref
cloud_download
Original Resource
url resource Institution
